WallStSmart

Envista Holdings Corp (NVST)vsWest Pharmaceutical Services Inc (WST)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

West Pharmaceutical Services Inc generates 13% more annual revenue ($3.07B vs $2.72B). WST leads profitability with a 16.1% profit margin vs 1.7%. WST trades at a lower P/E of 36.1x. NVST earns a higher WallStSmart Score of 56/100 (C).

NVST

Buy

56

out of 100

Grade: C

Growth: 7.3Profit: 4.5Value: 3.0Quality: 7.0
Piotroski: 5/9Altman Z: 1.47

WST

Buy

55

out of 100

Grade: C-

Growth: 4.7Profit: 8.0Value: 4.7Quality: 7.3
Piotroski: 5/9Altman Z: 4.91
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

NVSTSignificantly Overvalued (-131.0%)

Margin of Safety

-131.0%

Fair Value

$13.10

Current Price

$26.14

$13.04 premium

UndervaluedFair: $13.10Overvalued
WSTSignificantly Overvalued (-256.8%)

Margin of Safety

-256.8%

Fair Value

$68.99

Current Price

$247.02

$178.03 premium

UndervaluedFair: $68.99Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

NVST3 strengths · Avg: 8.7/10
Price/BookValuation
1.4x10/10

Reasonable price relative to book value

Revenue GrowthGrowth
15.0%8/10

15.0% revenue growth

EPS GrowthGrowth
31.5%8/10

Earnings expanding 31.5% YoY

WST2 strengths · Avg: 9.0/10
Altman Z-ScoreHealth
4.9110/10

Safe zone — low bankruptcy risk

Operating MarginProfitability
21.6%8/10

Strong operational efficiency at 21.6%

Areas to Watch

NVST4 concerns · Avg: 2.5/10
Return on EquityProfitability
1.6%3/10

ROE of 1.6% — below average capital efficiency

Profit MarginProfitability
1.7%3/10

1.7% margin — thin

P/E RatioValuation
93.0x2/10

Premium valuation, high expectations priced in

Altman Z-ScoreHealth
1.472/10

Distress zone — elevated risk

WST3 concerns · Avg: 3.3/10
P/E RatioValuation
36.1x4/10

Premium valuation, high expectations priced in

EPS GrowthGrowth
2.1%4/10

2.1% earnings growth

PEG RatioValuation
2.892/10

Expensive relative to growth rate

Comparative Analysis Report

WallStSmart Research

Bull Case : NVST

The strongest argument for NVST centers on Price/Book, Revenue Growth, EPS Growth. Revenue growth of 15.0% demonstrates continued momentum.

Bull Case : WST

The strongest argument for WST centers on Altman Z-Score, Operating Margin. Profitability is solid with margins at 16.1% and operating margin at 21.6%.

Bear Case : NVST

The primary concerns for NVST are Return on Equity, Profit Margin, P/E Ratio. A P/E of 93.0x leaves little room for execution misses. Thin 1.7% margins leave little buffer for downturns.

Bear Case : WST

The primary concerns for WST are P/E Ratio, EPS Growth, PEG Ratio.

Key Dynamics to Monitor

NVST profiles as a value stock while WST is a mature play — different risk/reward profiles.

WST carries more volatility with a beta of 1.18 — expect wider price swings.

NVST is growing revenue faster at 15.0% — sustainability is the question.

WST generates stronger free cash flow (175M), providing more financial flexibility.

Bottom Line

NVST scores higher overall (56/100 vs 55/100) and 15.0% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Envista Holdings Corp

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

Envista Holdings Corporation, develops, manufactures and markets dental products in the United States and internationally. The company is headquartered in Brea, California.

Visit Website →

West Pharmaceutical Services Inc

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

West Pharmaceutical Services, Inc. is a designer and manufacturer of injectable pharmaceutical packaging and delivery systems. The company is headquartered in Exton, Pennsylvania.

Want to dig deeper into these stocks?